Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma

El Beaino, 2018, Mesenchymal chondrosarcoma: a review with emphasis on its fusion-driven biology, Curr. Oncol. Rep., 20, 10.1007/s11912-018-0668-z Ostlere, 1999, Mesenchymal chondrosarcoma associated with Goldenhar's syndrome, Arch. Orthop. Trauma Surg., 119, 347, 10.1007/s004020050425 Sadashiva, 2016, Intracranial extraskeletal mesenchymal chondrosarcoma, World Neurosurg., 95, 618.e611, 10.1016/j.wneu.2016.08.049 Folpe, 2018, Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall, Hum. Pathol., 77, 28, 10.1016/j.humpath.2018.03.012 Wang, 2012, Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data, Genes Chromosomes Cancer, 51, 127, 10.1002/gcc.20937 Hogendoorn, P. C. W., Bovee, J. M. & Nielsen, G. P. Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: World Health Organization classification of tumours of soft tissue and bone, (eds Fletcher, C. D. M., Bridge, J. A., Hogendoorn, P. C. W. & Mertens, F.) 4th edn, Vol. 5, p.264 (World Health Organization, IARC, Lyon, 2013). Cesari, 2007, Mesenchymal chondrosarcoma. an analysis of patients treated at a single institution, Tumori J., 93, 423, 10.1177/030089160709300503 Xu, 2015, Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years, PLoS ONE, 10, e0122216, 10.1371/journal.pone.0122216 Schneiderman, 2017, Survival in mesenchymal chondrosarcoma varies based on age and tumor location: a survival analysis of the SEER database, Clin. Orthop. Relat. Res., 475, 799, 10.1007/s11999-016-4779-2 Frezza, 2015, Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study, Eur. J. Cancer, 51, 374, 10.1016/j.ejca.2014.11.007 Hilton, 2008, Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation, Nat. Med., 14, 306, 10.1038/nm1716 Salie, 2010, Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone, Bone, 46, 680, 10.1016/j.bone.2009.10.022 Xu, 2003, Review of the in vivo functions of the p160 steroid receptor coactivator family, Mol. Endocrinol., 17, 1681, 10.1210/me.2003-0116 Spencer, 1997, Steroid receptor coactivator-1 is a histone acetyltransferase, Nature, 389, 194, 10.1038/38304 Yin, 2007, MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2, Mol. Cancer, 6, 10.1186/1476-4598-6-51 Yoshida, 2014, PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells, Oncogene, 33, 5601, 10.1038/onc.2013.491 Xiao, 2018, Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications, Cancer Treat. Rev., 63, 61, 10.1016/j.ctrv.2017.12.001 Hagenbuchner, 2016, Targeting transcription factors by small compounds—current strategies and future implications, Biochem. Pharmacol., 107, 1, 10.1016/j.bcp.2015.12.006 Karlsson, 2020, High affinity between CREBBP/p300 and NCOA evolved in vertebrates, Protein Sci., 29, 1687, 10.1002/pro.3868 Keppel, 2011, Mapping unstructured regions and synergistic folding in intrinsically disordered proteins with amide H/D exchange mass spectrometry, Biochemistry, 50, 8722, 10.1021/bi200875p Aigner, 2000, Cell differentiation and matrix gene expression in mesenchymal chondrosarcomas, Am. J. Pathol., 156, 1327, 10.1016/S0002-9440(10)65003-1 Brown, 2003, Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications, Ann. Clin. Lab. Sci., 33, 131 Brown, 2004, Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma, Ann. Clin. Lab. Sci., 34, 397 van Oosterwijk, 2013, Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta as potential targets, Am. J. Pathol., 182, 1347, 10.1016/j.ajpath.2012.12.036 Wehrli, 2003, Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors, Hum. Pathol., 34, 263, 10.1053/hupa.2003.41 de Jong, 2016, Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line, Lab. Investig., 96, 1128, 10.1038/labinvest.2016.91 Sharifnia, 2017, Emerging opportunities for target discovery in rare cancers, Cell Chem. Biol., 24, 1075, 10.1016/j.chembiol.2017.08.002 Wolf, 2018, SCANPY: large-scale single-cell gene expression data analysis, Genome Biol., 19, 10.1186/s13059-017-1382-0 Benito-Gonzalez, 2014, Hey1 and Hey2 control the spatial and temporal pattern of mammalian auditory hair cell differentiation downstream of Hedgehog signaling, J. Neurosci., 34, 12865, 10.1523/JNEUROSCI.1494-14.2014 Ji, 2019, Single-cell RNA-seq analysis reveals the progression of human osteoarthritis, Ann. Rheum. Dis., 78, 100, 10.1136/annrheumdis-2017-212863 Carluccio, S. et al. Progenitor cells activated by platelet lysate in human articular cartilage as a tool for future cartilage engineering and reparative strategies. Cells9, 1052 (2020). Liu, 2020, mTOR at the nexus of nutrition, growth, ageing and disease, Nat. Rev. Mol. Cell Biol., 21, 183, 10.1038/s41580-019-0199-y Grignani, 2011, A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: an Italian Sarcoma Group study, Cancer, 117, 826, 10.1002/cncr.25632 Pillai, 2017, Rare cancers: challenges & issues, Indian J. Med. Res., 145, 17, 10.4103/ijmr.IJMR_915_14 Mitani, 2020, Small data challenges of studying rare diseases, JAMA Netw. Open, 3, e201965, 10.1001/jamanetworkopen.2020.1965 Alvi, 2017, Rare cancers: the greatest inequality in cancer research and oncology treatment, Br. J. Cancer, 117, 1255, 10.1038/bjc.2017.321 Nakashima, 1986, Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases, Cancer, 57, 2444, 10.1002/1097-0142(19860615)57:12<2444::AID-CNCR2820571233>3.0.CO;2-K Dahlin, 1962, Mesenchymal chondrosarcoma. Further observations on a new entity, Cancer, 15, 410, 10.1002/1097-0142(196203/04)15:2<410::AID-CNCR2820150225>3.0.CO;2-L Wang, 2021, Comparison of the major cell populations among osteoarthritis, Kashin-Beck disease and healthy chondrocytes by single-cell RNA-seq analysis, Cell Death Dis., 12 Colom, 2021, Mutant clones in normal epithelium outcompete and eliminate emerging tumours, Nature, 598, 510, 10.1038/s41586-021-03965-7 Muller, 2005, Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton, Mod. Pathol., 18, 1088, 10.1038/modpathol.3800391 Eekels, 2012, A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation, Gene Ther., 19, 1058, 10.1038/gt.2011.191 Bilanges, 2007, Tuberous sclerosis complex proteins 1 and 2 control serum-dependent translation in a TOP-dependent and -independent manner, Mol. Cell Biol., 27, 5746, 10.1128/MCB.02136-06 Shakked, 2012, Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases, Arch. Pathol. Lab. Med., 136, 61, 10.5858/arpa.2010-0362-OA Guo, 2015, A case of mesenchymal chondrosarcoma arising from the femoral vein with 8 years of follow-up, Ann. Vasc. Surg., 29, 1455 e1451, 10.1016/j.avsg.2015.04.086 Zhang, 2007, PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR, J. Clin. Investig., 117, 730, 10.1172/JCI28984 Ho, 2012, PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma, Cancer Res., 72, 4515, 10.1158/0008-5472.CAN-12-1319 Yang, 2006, P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin, Cell, 127, 139, 10.1016/j.cell.2006.08.036 Oh, 2008, Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells, Mol. Cell Biol., 28, 6580, 10.1128/MCB.00118-08 Wang, 2016, Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3beta/beta-catenin signaling, Theranostics, 6, 1205, 10.7150/thno.15083 Abdel-Rahman, 2017, Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations, World J. Gastroenterol., 23, 3440, 10.3748/wjg.v23.i19.3440 Tepes, P. S., et al. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression. Elife 10, e66109 (2021). Yoshida, 2020, Applications of patient-derived tumor xenograft models and tumor organoids, J. Hematol. Oncol., 13, 4, 10.1186/s13045-019-0829-z Nicolle, 2019, Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression, Nat. Commun., 10, 10.1038/s41467-019-12525-7